AstraZeneca to launch acalabrutinib in IndiaApril 4, 2020
AstraZeneca Pharma India Limited said the company received permission from Drugs Controller General of India (DCGI) to import and market acalabrutinib (Calquence) 100 mg capsules.
The drug is indicated for use in the treatment of patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Acalabrutinib is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK). The drug binds covalently to BTK, thereby inhibiting its activity. In B-cells, BTK signalling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.